Halozyme

Shares of Halozyme Therapeutics Inc. () are down 37% from their 52-week high of $59.46, recorded last December, and trade around $37.Halozyme is a biopharmaceutical company, whose ENHANZE drug delivery is licensed to pharma and biotech companies, including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.ENHANZE is a patented, commercial platform... + full article